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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the clinical effects (benefits and harms) of intermittent flushing of heparin versus 0.9% sodium chloride to prevent occlusion
in long term central venous catheters (CVCs) in infants and children.
B A C K G R O U N D
Description of the condition
A central venous catheter (CVC) is a catheter which is inserted
into a large central vein, with the tip of the catheter ideally placed
within the superior vena cava (Schuster 2000). This enables the
administration of medications and fluids, as well as the collection
of blood specimens to avoid unnecessary venipunctures. The use
of long termCVCs for the management of chronic medical condi-
tions in infants and children has greatly improved the quality and
safety of care provision. Long term CVCs are typically inserted
when the administration of intravenous medication or nutritional
support is required over a considerable time period. Hypertonic
medications such as vesicant chemotherapy drugs, certain antibi-
otics, other supportive drugs and parenteral nutrition are not able
to be safely administered through peripheral venous catheters. For
children with cancer and other chronic medical conditions who
require suchmedications, this safety issue is overcome by the inser-
tion of a CVC which commonly remains in place for the duration
of treatment (Gonzalez 2012). There are three types of long term
CVCs: tunnelled catheters; implanted ports; and peripherally in-
serted central catheters (PICC). A tunnelled CVC is surgically in-
serted under the skin, with the catheter lumen(s) typically exiting
from the chest or neck. An implanted port is also surgically im-
planted, but is placed entirely under the skin. The port reservoir
is accessed with a needle through the skin. A PICC line is inserted
into a central vein through the arm and thus is a narrower catheter.
Adverse events associated with CVCs may cause complications
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in up to 46% of children (Athale 2012). Adverse events include
mechanical failure, infections and thrombotic complications, all
of which can effect patient morbidity and mortality (Baskin 2009;
Fratino 2005; Stocco 2012; Wong 2012). Mechanical failure is
often attributed to catheter occlusion. Over time, it is common
for a fibrin sheath to develop at the tip of the catheter. This may
prevent aspiration of blood from the catheter and cause resistance
when infusing fluids. An intraluminal clot can also occur, totally
occluding the catheter. Occlusion can result in the need for the
catheter to be removed (and replaced), interrupting and delaying
treatment of the underlying disease (Shah 2007). Occlusions of
CVCs are estimated to occur in 14% to 36%of patients within one
to two years of catheter insertion (Fratino 2005) or at an incidence
rate of 1.35 per 1000 catheter days (95% confidence interval (CI)
1.1 to 1.63) (Revel-Rilk 2010). Incidence rates of blood stream
infection associated with CVCs differ depending upon the type of
catheter, with rates reported between 1.40 per 1000 catheter days
(95% CI 1.06 to 1.82) and 0.46 per 1000 catheter days (95% CI
0.29 to 0.69). Thrombotic complications are the rarest adverse
events reported in children, with a lower incidence rate of 0.08
per 1000 catheter days (95% CI 0.04 to 0.16) (Fratino 2005).
Description of the intervention
A flush refers to solution being injected to clean the catheter of
blood or fibrin buildup. This is commonly used when the catheter
is accessed, between administration of medications, or before and
after collection of blood specimens. A positive pressure lock is used
when the catheter will not be accessed for a period of time, and
refers to the technique used to ensure blood does not flowback into
the catheter after it is flushed, which may otherwise clot and cause
occlusion. Tunnelled CVCs and PICC lines are typically flushed
and locked weekly, while implanted ports are flushed and locked
every 4 to 6weeks. A typical intervention for tunnelled catheters in
children is to use between 1 ml to 3 ml (depending on the volume
of the catheter) of 10 units/ml of heparin for a 24 hour to 7 day
lock. For implanted ports, 5 mls of 100 units/ml is typically used
for a 30 day lock (Davis 2013). However, there is debate regarding
the effectiveness of heparin to prevent occlusion over such time
periods, given its short half life (Young 2008). The evidence to
support the use of heparin to prevent occlusion in adult CVCs is
inconclusive and there is growing evidence to support the use of
0.9% sodium chloride to lock CVCs, particularly in the paediatric
population (Bertoglio 2012; Lee 2005).
How the intervention might work
Heparin is used to prevent occlusion because of its anti-coagulant
properties which are believed to prevent thrombus forming in
the catheter. Alternatively 0.9% sodium chloride, when used with
pulsatile flushing techniques and a positive pressure lock or positive
displacement device, may be as effective in preventing thrombus
formation in catheters - eliminating the need for heparin to be
used.
Why it is important to do this review
Practices vary among institutions because of the lack of evidence
regarding best practice to prevent occlusion of CVCs. The use
of heparin is not risk free and in certain instances may actually
cause harm including heparin-induced thrombocytopenia (HIT)
(Barclay 2012). The mechanism of haemostasis in children is dif-
ferent when compared to adults, particularly in infants and very
young children (Monagle 2010). Additionally, treatments for dis-
eases such as cancer involve the use ofmedications which can affect
coagulation; thus the use of heparin to prevent CVC occlusion
should be judicious and evidence-based. While the risks of adverse
effects from the use of heparin may be regarded as less than the
potential occlusion of a catheter and subsequent replacement, it is
important to ensure interventions are based on evidence.
There have been several trials (Goosens 2013; Schallom 2012;
Schilling 2006), a systematic review (Mitchell 2009), and a
Cochrane review protocol to review the use of heparin versus 0.9%
sodium chloride to prevent occlusions in CVCs in the adult pop-
ulation (Lopez-Briz 2010). As evidence from adult studies is not
directly transferable to paediatrics, a systematic review focused on
infants and children is required.
O B J E C T I V E S
To assess the clinical effects (benefits and harms) of intermittent
flushing of heparin versus 0.9% sodium chloride to prevent occlu-
sion in long term central venous catheters (CVCs) in infants and
children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include only randomised controlled trials.Due topotential
bias, we will exclude studies that use alternative methods (quasi-
randomised) to allocate participants to a control or intervention
group.
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Types of participants
The study population comprises infants and children aged 1 to
18 years who have a CVC (tunnelled catheter or implanted port),
inserted for long term venous access. Studies of infants or chil-
dren with Midline catheters or PICCs are beyond the scope of
this review and will be excluded. There are no restrictions on the
insertion site, or catheter tip placement site (superior or inferior
vena cava). There will be no restrictions on the healthcare setting
in which the study has been conducted, e.g. tertiary hospital or
community setting. Where studies have a mixed population that
includes infants, children and adults, we will include data from
infants and children only. If this information is not presented in
the article, we will contact the study authors to attempt to obtain
age-stratified results. If we are unable to contact the study authors,
and children and infants comprise a proportion greater than 20%
of the study population, we will include the appropriate threshold
proportion. If we are unable to obtain any information regarding
the proportion of infants and children in the study population,
we will exclude the study from the review.
Types of interventions
The intervention of interest is the intermittent (any time fre-
quency) flushing of heparin (any dose or concentration) compared
with intermittent flushing with 0.9% sodium chloride solution
(alone, or in combination with pulsatile flushing techniques, pos-
itive displacement devices or positive pressure lock) delivered with
the intention to prevent occlusion of the CVC.
Types of outcome measures
Primary outcomes
• Occlusion of the CVC, determined by the inability to
infuse fluids through the catheter
• Duration in weeks of catheter placement
• Any adverse event associated with CVCs (catheter-related
thrombosis, sepsis, central line associated blood stream infection
(CLABSI) or colonisation of the catheter, allergic reaction,
haemorrhage, heparin-induced thrombocytopaenia (HIT),
elevated hepatic enzymes)
Outcomes will not be considered a part of eligibility criteria.
Secondary outcomes
• Ability to withdraw blood from the CVC
• Any use of urokinase or recombinant tissue plasminogen
such as alteplase
• Incidence of removal and re-insertion of the catheter
Search methods for identification of studies
No restrictions will be placed on language.
Electronic searches
The Cochrane Peripheral Vascular Diseases Group Trials
Search Co-ordinator (TSC) will search the Group’s Spe-
cialised Register and the Cochrane Central Register of Con-
trolled Trials (CENTRAL), part of The Cochrane Library (
www.thecochranelibrary.com). See Appendix 1 for details of the
search strategy which will be used to search CENTRAL. The Spe-
cialised Register is maintained by the TSC and is constructed from
weekly electronic searches of MEDLINE, EMBASE, CINAHL,
AMED, and through handsearching relevant journals. The full
list of the databases, journals and conference proceedings which
have been searched, as well as the search strategies used are de-
scribed in the Specialised Register section of the Cochrane Periph-
eral Vascular Diseases Group module in The Cochrane Library (
www.cochranelibrary.com).
The following trial databases will be searched by the TSC for
details of ongoing and unpublished studies:
• World Health Organization International Clinical Trials
Registry http://apps.who.int/trialsearch/
• ClinicalTrials.gov http://clinicaltrials.gov/
• Current Controlled Trials http://www.controlled-
trials.com/
• Nederlands Trials Register http://www.trialregister.nl/
trialreg/admin/rctsearch.asp
Searching other resources
We will screen the reference lists of retrieved articles for additional
studies.Wewill attempt to contact authors of any studies identified
in unpublished literature to obtain further data.
Data collection and analysis
Selection of studies
Two review authors (NB, RE) will independently review all titles
and abstracts retrieved to assess eligibility against inclusion criteria.
Where disagreement exists regarding the inclusion of a study, the
third author (RC) will be consulted. The full text of all potentially
eligible studies will be obtained and authors of primary studies
will be contacted to clarify data if necessary. A flowchart based
upon the Preferred Reported Items for Systematic Reviews and
Meta-Analysis (PRISMA) (Moher 2009) statement will be used to
document results and will be presented in the review. Data will be
recorded regarding the results of all searches undertaken including:
database searched; date; limiters, and number of results.
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Data extraction and management
Data extraction will be completed independently by NB and RE
and documented on the PVD Group forms for dichotomous and
continuous data. Data will be collected regarding the population,
intervention(s) and relevant outcomes for each study. Any dis-
agreement will be resolved by discussion between all review au-
thors (NB, RE, RC).
Assessment of risk of bias in included studies
Bias will be assessed within studies using the tool described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). The following domains will be reported: sequence genera-
tion; allocation concealment; blinding; incomplete data; selective
outcome reporting, and other biases. If necessary, primary authors
will be contacted to clarify any information. Disagreement regard-
ing the assessment of bias will be resolved by discussion among all
review authors (NB, RE, RC).
Measures of treatment effect
Odds ratios (OR) or relative risks (RR) with 95% confidence in-
tervals (CI) will be calculated for dichotomous data (e.g. CVC oc-
clusion, adverse event etc). Descriptive statistics including mean
differences (MD) and standard deviations (SD) will be presented
for continuous data (e.g. duration of catheter placement). Time-
to-event data (occlusion) will be reported as hazard ratios (HR)
with 95% CI.
Unit of analysis issues
The unit of analysis for each trial will be identified. It is anticipated
that outcomes for intervention or control groups will be reported
as single effectmeasurements from each participant.Where results
are reported from cluster randomised controlled trials, cross-over
trials or repeated measurements of the same outcome, the appro-
priate design effect will be taken into consideration to avoid unit
of analysis error.
Dealing with missing data
Primary authors of studies will be contacted to obtain any missing
data. All data will be assessed for potential mislabelling and we will
not make assumptions of missing data in order to include these
in any analysis. Where data are missing and cannot be obtained,
they will be excluded from the analysis.
Assessment of heterogeneity
If feasible, visual inspection of forest plots and the Chi2 test (P
value < 0.05) will be used to test for heterogeneity between effect
sizes of included studies. Inconsistency between trials will be de-
scribed by assessing the I2 statistic and the variability between the
effect estimates. A value of I2 greater than 50% will be considered
to represent substantial heterogeneity (Higgins 2011), and we will
explore heterogeneity and possible reasons.
Assessment of reporting biases
If feasible, publication bias will be assessed using funnel plots and
Egger’s tests. Additionally reporting bias will be reduced by search-
ing multiple electronic databases, proceedings of conferences and
scientific meetings and trial registries. There will be no language
restriction. Duplicates of the same trials will be excluded to avoid
duplicate publication bias.
Data synthesis
We will enter data into RevMan (RevMan 2012) and undertake
analysis according to recommended guidelines (Higgins 2011).
Effect sizes across studies will be combined using a fixed-effect
model. Where substantial heterogeneity exists, data will be pooled
using the random-effects model. Confidence interval limits will
be set at 95%. If we are not able to undertake a pooled analysis,
results will be descriptively summarised.
Subgroup analysis and investigation of heterogeneity
Where sufficient studies are available for analysis, subgroup anal-
ysis will be performed regarding: type of CVC (tunnelled catheter
or implanted port); insertion site and/or catheter tip placement
site; age group, and diagnosis.
Sensitivity analysis
Sensitivity analysis will be undertaken to examine the effects of
different trials and their methodology. The rigour of results will
also be assessed by comparing different measures of effect sizes
(OR, RR, MD) and random-effects or fixed-effect models.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Heparin] explode all trees
#2 (hep* or UH or UFH or LMWH):ti,ab,kw
#3 MeSH descriptor: [Sodium Chloride] this term only




#8 #1 or #2
#9 #3 or #4 or #5 or #6 or #7
#10 #8 and #9
#11 MeSH descriptor: [Catheterization, Central Venous] this term only
#12 MeSH descriptor: [Catheterization] this term only
#13 MeSH descriptor: [Catheters, Indwelling] explode all trees
#14 catheter*:ti,ab,kw
#15 cannula*:ti,ab,kw
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(Continued)
#16 CVC* or PICC:ti,ab,kw
#17 port*:ti,ab,kw
#18 #11 or #12 or #13 or #14 or #15 or #16 or #17
#19 #10 and #18 in Trials
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